Larvol Delta - BioPath-Receives-Notice-of-Allowance-for-Strategic-Patent-for-Prexigebersen-in-Combination-with-Front-Line-Cytidine-Analogues-or-BcrAbl-Tyrosine-Kinase-Inhibitors-in-a-Variety-of-Cancers

prexigebersen (BP1001) - Bio-Path

https://www.globenewswire.com/news-release/2020/10/22/2112656/0/en/Bio-Path-Receives-Notice-of-Allowance-for-Strategic-Patent-for-Prexigebersen-in-Combination-with-Front-Line-Cytidine-Analogues-or-Bcr-Abl-Tyrosine-Kinase-Inhibitors-in-a-Variety-of.html

Oct 22, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next